Glaukos Announces Global Licensing Agreement Amendment with Intratus to Include the Treatment of Presbyopia
Glaukos announced that it has entered into an amended licensing agreement with Intratus under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, noninvasive drug delivery platform (the Eyelid Drug Delivery Platform) for application in the treatment of presbyopia.
Financial terms of the agreement were not disclosed.
The addition of presbyopia expands upon the existing agreement between the two parties announced on July 22, 2019, under which Glaukos secured a global exclusive license to research, develop, manufacture and commercialize the Eyelid Drug Delivery Platform for use in the treatment of dry eye disease, glaucoma, and other corneal disorders such as allergy, blepharitis, conjunctivitis and related conditions. Additionally, the amendment includes a mechanism to further expand the existing agreement to other indications, applying the active pharmaceutical ingredients being advanced by Glaukos in glaucoma, corneal disorders and presbyopia to new ophthalmic fields.
“We are excited to expand our partnership with Intratus by adding presbyopia as a new investigational application for this novel drug delivery platform and build upon the promising R&D work we’ve completed thus far in dry eye disease, glaucoma and other corneal disorders,” Thomas Burns, Glaukos president and chief executive officer, said in a company news release. “The Eyelid Drug Delivery Platform uses a differentiated, noninvasive, patient-friendly, transdermal approach and is highly complementary to our expanding portfolio of sustained pharmaceutical platforms in glaucoma, corneal health and retinal disease.”
“Intratus is pleased to have our platform technology continue its expansion through a second license with Glaukos,” said Aaron Dyer, Intratus president and chief executive officer. “We look forward to the progress Glaukos will continue to make and ultimately the restoration of sight we hope to provide for patients.”
The Eyelid Drug Delivery Platform’s patented cream-based drug formulations are applied to the outer surface of the eyelid for transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. Early human studies with this novel delivery system have demonstrated efficacy without the side effects often associated with drugs delivered as topical eye drops, according to a Glaukos news release.
Under the expanded agreement, Glaukos will obtain an exclusive global license to Intratus’ drug delivery technology for use in the treatment of presbyopia, in addition to glaucoma and corneal disorders, including dry eye disease, allergy, blepharitis, conjunctivitis and related conditions.